Journal of Clinical Oncology · 2024 · 159 citations · 19 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyCancer ImmunotherapyHer2-positive Breast CancerMetastatic Breast CancerTargeted Cancer TherapyTargeted TherapyTopoisomerase InhibitorsAntibody-directed ProdrugsAntibody-drug Conjugate TherapyHer2-positive Breast Cancer ImmunotherapyHer2-positive Breast Cancer TherapyMetastatic Breast Cancer TreatmentMetastatic Her2-positive Breast CancerTopoisomerase I InhibitorsTriple-negative Breast Cancer Therapy
PURPOSE: Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate consisting of a humanized antitrophoblast cell-surface antigen 2 (TROP2) monoclonal antibody linked to a potent, exatecan-derived topoisomerase I inhibitor payload via a plasma-stable, selectively cleavable linker. PATIENTS AND METHODS: TROPION-PanTumor01 (ClinicalTrials.gov identifier: NCT03401385) is a phase I, dose-escalation, and dose-expansion study evaluating Dato-DXd in patients with previously treated solid tumors. The primary study objective was to assess the safety and tolerability of Dato-DXd. Secondary objectives included evaluation of antitumor activity and pharmacokinetics. Results from patients with advanced/metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer (BC) or triple-negative BC (TNBC) are reported. RESULTS: At data cutoff (July 22, 2022), 85 patients (HR+/HER2- BC = 41, and TNBC = 44) had received Dato-DXd. The objective response rate by blinded independent central review was 26.8% (95% CI, 14.2 to 42.9) and 31.8% (95% CI, 18.6 to 47.6) for patients with HR+/HER2- BC and TNBC, respectively. The median duration of response was not evaluable in the HR+/HER2- BC cohort and 16.8 months in the TNBC cohort. The median progression-free survival in patients with HR+/HER2- BC and TNBC was 8.3 and 4.4 months, respectively. All-cause treatment-emergent adverse events (TEAEs; any grade, grade ≥3) were observed in 100% and 41.5% of patients with HR+/HER2- BC and 100% and 52.3% of patients with TNBC. Stomatitis was the most common TEAE (any grade, grade ≥3) in both HR+/HER2- BC (82.9%, 9.8%) and TNBC (72.7%, 11.4%) cohorts. CONCLUSION: In patients with heavily pretreated advanced HR+/HER2- BC and TNBC, Dato-DXd demonstrated promising clinical activity and a manageable safety profile. Dato-DXd is currently being evaluated in phase III studies.
19
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Fátima Cardoso, A. Costa, Elżbieta Senkus et al. · Annals of Oncology · 2016 · 2.1K citations · Full text
Medicine, Oncology, Breast Oncology +11
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi, Cristina Saura, Toshinari Yamashita et al. · New England Journal of Medicine · 2019 · 2K citations · Full text
Medicine, Oncology, Pharmacology +17
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney et al. · New England Journal of Medicine · 2021 · 1.5K citations · Full text
Medicine, Oncology, Pharmacology +17